SEC Form 4 · accession 0001415889-18-000152
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Caribou Biosciences, Inc.
10% Owner
Period of report
Jan 29, 2018
Accepted (ET)
Jan 30, 2018 · 5:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 29, 2018 | S | 550,645 | $26.78 | D | 3,994,355 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.75 to $26.97, inclusive. The reporting person undertakes to provide to Intellia Therapeutics, Inc., any security holder of Intellia Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 1 to this Form 4.
- F2This Form 4 is filed on behalf of (i) Caribou Therapeutics Holdco, LLC, the direct holder of the shares, and (ii) Caribou Biosciences, Inc. Caribou Therapeutics Holdco, LLC is a wholly-owned subsidiary of Caribou Biosciences, Inc., and thus Caribou Biosciences, Inc. may be deemed to share voting and dispositive power with respect to the shares held by Caribou Therapeutics Holdco, LLC. Caribou Biosciences, Inc. disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, if any.